Botulinum Toxin Use in Movement Disorders and Spasticity

2017 ◽  
pp. 375-383
Author(s):  
Karen Frei ◽  
Daniel Truong
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders

scholarly journals Botulinum Toxin in Movement Disorders: An Update

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 42
Author(s):  
Charenya Anandan ◽  
Joseph Jankovic
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Neurological Disorders ◽  
Active Drug ◽  
Therapeutic Agents ◽  
Therapeutic Modality ◽  
Review Of The Literature ◽  
Pilot Studies ◽  
The Us ◽  
Novel Applications

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period

2002 ◽  
Vol 17 (6) ◽  
pp. 1288-1293 ◽  
Author(s):  
G-Y.R. Hsiung ◽  
S.K. Das ◽  
R. Ranawaya ◽  
A.-L. Lafontaine ◽  
O. Suchowersky
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Term Efficacy

Movement Disorders

2009 ◽  
pp. 551-574
Author(s):  
John N. Caviness
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Surface Emg ◽  
Involuntary Movements ◽  
Botulinum Toxin Injections

Surface EMG, EEG, and elicited response results provide a simple and noninvasive means of studying movement disorders. These techniques are particularly helpful in classifying involuntary movements such as tremor and myoclonus. In addition, EMG can assist with designing and performing botulinum toxin injections.

VAIKŲ, SERGANČIŲ CEREBRINIU PARALYŽIUMI, ILGALAIKIO GYDYMO BOTULINO TOKSINU POVEIKIS ČIURNOS SĄNARIO JUDESIO AMPLITUDEI IR VAIKŲ MOBILUMUI

2015 ◽  
Vol 25 (1) ◽  
pp. 58-65
Author(s):  
Laima Mikulėnaitė ◽  
Jovita Petrulytė ◽  
Anastasija Žernakova
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Ankle Joint ◽  
Movement Disorders ◽  
Treatment Time ◽  
Term Treatment ◽  
Clinical Syndrome ◽  
Functional Movement ◽  
Long Term Treatment

Introduction. Spasticity – the basic and the most common clinical syndrome of cerebral palsy. Most of the time child’s functional and movement disorders depend on this. Botulinum toxin is a drug that relaxes muscles by blocking the release of acetylcholine (ACH) in neuro muscular connection and reduces level of spasticity. The short-term effect of BTX has been proven in scientific literature and it is well known. The effect of treatment with BTX –A in a long-term remains insufficiently studied. Purpose. To evaluate the effect on changes in child’s with cerebral palsy conditions of ankle and child’s mobility over the long time (over 1 year) in the treatment with BTX-A. Method. 98 children with cerebral palsy were treated. The main indication for the treatment of BTX- A was a dynamic ankle joint contracture, resulting in functional status or movement disorders. Condition of all children were evaluated 1 month before starting the treatment with BTX; prior to each injection; within 1 – 2 months after the beginning of treatment with Dysport and after 4 months while planning further treatment with botulinum toxin. The passive ROM of child’s ankle joint was assessed with goniometer measuring the ankle of dorsiflexion while stretching the child’s knee. The functional movement of the child was assessed using the GMFM -88 scale. Results. The average age of children after first BTX-A injection was 33.29 ± 16.235 months. The majority of children (n = 45) were mobile belonging to I - II level at the GMFCS and partly mobile belonging to level III (n = 35). The number of injections of BTX –A ranged from 2 to 8 times per child. The data suggest that despite long-term treatment with BTX –A and physical therapy with the increase of child’s age the contracture of the ankle joint forms. In all cases the only criteria which are statistically significant is time. It means that passive changes in ankle joint dorsiflexion depend on its treatment time. Assessment of child’s functional movement with GMFM -88 scale showed that with each injection of BTX –A the functional movement of a child is enhanced. The highest improvement in motion has been established after the sixth injection of botulinum toxin. Conclusion. Treatment with BTX-A doesn’t have an impact on increase of passive amplitude of ankle and it doesn‘t affect the formation of contractures. Functional movements of a child improvement depend on treatment time: the best result was reached after sixth injection of BTX.

Guidelines for the therapeutic use of botulinum toxin in movement disorders

1998 ◽  
Vol 19 (3) ◽  
pp. 189-190 ◽  
Author(s):  
C. A. Pagni ◽  
G. Abbruzzese ◽  
A. Berardelli
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Therapeutic Use

Botulinum toxin in movement disorders

2018 ◽  
Vol 66 (7) ◽  
pp. 79 ◽  
Author(s):  
Sanjay Pandey ◽  
Priyanka Tater
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders
Sign in / Sign up

Export Citation Format

Share Document